Loading...
Loading...
Targacept, Inc.
TRGT, a clinical-stage biopharmaceutical company
developing novel NNR Therapeutics ™, today announced that Stephen A. Hill,
M.D. has been appointed as President and Chief Executive Officer. Dr. Hill is
expected to start with Targacept on December 1, 2012 and will also join
Targacept's Board of Directors.
Dr. Hill brings over 20 years of industry experience to the role, having
served previously as President and Chief Executive Officer of Solvay
Pharmaceuticals, Inc. and ArQule, Inc. At Solvay, he led an organization of
over 1,200 employees until its acquisition by Abbott Laboratories in 2010. Dr.
Hill's responsibilities included the direct management of the U.S. commercial
organization and administrative support of U.S.-based clinical development,
project management, quality, regulatory affairs and new business development.
At ArQule, he led a successful transition from a fee-for-service discovery
chemistry model to an enterprise with a proprietary clinical-stage pipeline.
Prior to ArQule, Dr. Hill held several leadership positions with F.
Hoffmann-La Roche Ltd., including Global Head of Clinical Development.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsManagement
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in